Diabetic Macular Edema

This HCPLive Five episode focuses on 5 key ophthalmology updates from the ASRS2025 conference.

A month with few regulations instead saw significant research advancements presented at the American Society of Retina Specialists’ 2025 meeting.

The larger dose exhibited better gains in best-corrected visual acuity with fewer injections during the study period.

The combination therapy of aflibercept and micropulsed yellow laser treatment results in good anatomical responses and substantially fewer intravitreal injections.

EYP-1901 successfully achieved an extended time to first supplemental treatment versus aflibercept, indicating a potential for further dose interval extension.

Results from an extension study of the PHOTON trial indicate longer-lasting visual and anatomic improvements in patients receiving aflibercept 8mg versus 2mg.

A recent analysis of data from the phase 3 YOSEMITE/RHINE trials has indicated a greater reduction in hard exudates using faricimab versus aflibercept.

In a trial studying faricimab’s efficacy in Black, Hispanic/Latino, and Native American patients with DME, investigators found results consistent with the YOSEMITE/RHINE trials.

Our recap of the first half of 2025 highlights 5 regulatory updates, 5 trial announcements, and 3 top perspectives in eyecare.

Our Q2 2025 recap for ophthalmology highlights 5 regulatory updates, 5 important trial announcements, and top perspectives in eyecare.

June was characterized by HCPLive’s coverage of the AOA 2025 Conference in Minneapolis and a host of cross-specialty disease indicators and drug uses.

If approved, lamivudine may bring DME treatment and better vision outcomes to communities who cannot afford more costly intravitreal injections.

This May was characterized by HCPLive’s coverage of the ARVO and Envision conferences, as well as a slew of FDA approvals towards the end of the month.

A retrospective study indicated the safety and efficacy of FA implants, exhibiting its success in lowering central retina thickness.

Recent results have confirmed faricimab’s efficacy, although a small sample size and short follow-up period invite further studies.

Stay updated with the latest healthcare breakthroughs, including FDA approvals and innovative treatments, in this week's essential news roundup for professionals.

Panretinal photocoagulation and anti-VEGF therapy combined also results in better BCVA and were less likely to require additional treatment within 1 year.

While aflibercept 8 mg and faricimab both trigger intraocular pressure, the effects are transient and no more significant than other anti-VEGF treatments.

Triamcinolone acetonide injections effectively prevent diabetic macular edema after vitrectomy, highlighting its potential in postoperative care.

Susvimo is the first FDA-approved continuous delivery treatment for diabetic retinopathy capable of maintaining vision through one refill per 9 months.

Findings suggest a connection between RVO history and cystoid macular edema with the risk of developing postoperative macular edema after uneventful cataract surgery.

Stay updated with the latest healthcare breakthroughs, including cholesterol treatments and innovative therapies for AMD and psoriasis, in this week's roundup.

UBX1325 exhibited noninferiority to aflibercept in difficult-to-treat diabetic macular edema, while maintaining a favorable safety profile in the ASPIRE study.

April sees mixed outcomes in FDA approvals, with promising gene therapies advancing while others face setbacks, highlighting ongoing challenges in ocular treatments.

Clinical evidence may not reflect the incidence of IOI in real-world applications treating age-related macular degeneration and diabetic macular edema.